Form 4: Immix Biopharma Director Receives Equity Grant

Director Helen C. Adams acquired 6,250 restricted stock units and 12,500 stock options as part of an equity incentive plan.

Summary

• Director Helen C. Adams was granted 6,250 restricted stock units (RSUs) on May 22, 2026.
• The director also received a grant of 12,500 stock options with an exercise price of $8.78.
• The RSUs vest on the earlier of the one-year anniversary of the grant or the 2027 annual meeting.
• The stock options vest in equal monthly installments over 12 months, subject to continued board service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral for the stock price.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.
• Retention of board expertise through standard incentive vesting schedules.

Negatives

• Potential for future dilution of existing shareholders upon the exercise of options and vesting of RSUs.

Risks

• Continued service requirements for vesting may be impacted by board turnover.
• Market price volatility could affect the value of the granted equity instruments.

Future Outlook

The equity grants are subject to continued service on the Board of Directors through the respective vesting dates.

Management Comments

• The grants were issued pursuant to the Issuer's 2021 Equity Incentive Plan.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the biotechnology sector to ensure board alignment with long-term clinical and commercial milestones.

Comparison to Industry Standards

• The use of 12-month vesting schedules for director equity is consistent with standard practices for small-cap biotech firms.
• The grant size is typical for non-executive director compensation packages in the industry.

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual exercise of these options.

Next Steps

• Vesting of RSUs on the earlier of May 22, 2027, or the 2027 Annual Meeting.
• Monthly vesting of stock options over the next 12 months.

Key Dates

Keywords

Immix Biopharma, IMMX, Form 4, Director Compensation, Equity Incentive Plan, Insider Transaction